AVII - Sector: Healthcare --- Industry: Biotechnology & Drugs

[setravis]

bizjournals.com
AVI Biopharma gets patent notification
Thursday August 3, 5:42 pm ET


Portland bioscience company AVI Biopharma Inc. received notices of allowance from the U.S. Patent Office, meaning that AVI is entitled to a patent. The patents are for two AVI-developed treatments for vascular injury.
CEO Denis Burger said the two patents will strengthen AVI's (NASDAQ: AVII - News) position in the important cardiovascular health market.

Published August 3, 2006 by The Business Journal

[setravis]

• AVI BioPharma Earnings Call scheduled for Tue, Aug 8
CCBN (Tue, Aug 1) 


Technicals
Close Above the 13-day EMA

Last Price Quote is:
3.69%above 13-day EMA
-16.47%below 50-day EMA
RS Rating: 3 

Fundamentals
Earnings Expected on Aug 8

Key Data:
Market Cap (M): $136.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/08/2006
Last Analyst Rating: Mkt Outperform

[Melf Elf]

Oliver,

AVII broke out of a Symmetrical Triangle to the upside on May 9, and closed at 7.26.  The next session, it had a crash opening at 5.89, breaking the  Symmetrical Triangle pattern at 6.11 to the downside, putting a target of 2.84 IN PLAY.  Math is on the chart.

May 26, a few days after it was announced that AVII would be included in the Biotech Index, AVII closed at 4.77, and MACD crossed above its signal line.

AVII had formed a little base over the prior two weeks, and the crash gap overhead was unfilled.  Should we have taken the MACD crossover as a buy signal?

See next post.

[Melf Elf]

Oliver,

The 4.77 close on May 26, the day of the MACD crossover above its signal line, was as high as AVII got.  It gapped down the next day, and the 2.84 target MADE, and more.

In bearish charts like AVII and ESLR, MACD crossovers, particularly from well below zero, tend to be false "buy" signals, and they produce short-term rallies, or even occur at an exact top, as it did in AVII on May 26.

Bullish signals from indicators in charts that are bearish are suspect.

[setravis]

For AVII to succeed , New management is so much needed.
May have found a bottom.
Burger must go.......
Chairman, Chief Exec. Officer and Member of Exec. Committee.


Technicals
Close Above the 13-day EMA

Last Price Quote is:
5.12%above 13-day EMA
-13.58%below 50-day EMA
RS Rating: 5 

Fundamentals
Key Data:
Market Cap (M): $142.38 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/10/2006
Last Analyst Rating: Mkt Outperform

[tokyopua]

Oliver,

The 4.77 close on May 26, the day of the MACD crossover above its signal line, was as high as AVII got.  It gapped down the next day, and the 2.84 target MADE, and more.

In bearish charts like AVII and ESLR, MACD crossovers, particularly from well below zero, tend to be false "buy" signals, and they produce short-term rallies, or even occur at an exact top, as it did in AVII on May 26.

Bullish signals from indicators in charts that are bearish are suspect.

Hi Melf,

Thanks for your analysis on charts like these and SVA, etc.  I was wondering if the same thing is going on over at GNBT?  I am basically even in it, and it looks like it may have hit a triple bottom, but I am curious about your take on it (I posted in a previous 3SOF thread called Catching the Falling Knife, btw, dont mean to derail this thread, sorry).

[la-onda]

STRONG BUY REPORT:
http://www.jmdutton.com/research/avii/reports/avii_report_081806.pdf

[setravis]

Another nice day.... Good volume.
Volume: 1,067,069
Avg Vol (3m): 796,789

AVI BIOPHARMA INC (NasdaqGM:AVII) Delayed quote data 
After Hours (RT-ECN): 3.43  0.13 (3.94%)

Technicals
Percentage Gainer

Last Price Quote is:
15.18%above 13-day EMA
-4.11%below 50-day EMA
RS Rating: 9 

Fundamentals
Key Data:
Market Cap (M): $142.38 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/10/2006
Last Analyst Rating: Mkt Outperform

[setravis]

Press Release Source: AVI BioPharma


Dutton Associates Announces Investment Opinion: AVI BioPharma Raised To Strong Speculative Buy Rating In Update Coverage By Dutton Associates
Friday August 18, 12:00 pm ET


EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Aug. 18, 2006--Dutton Associates updates its coverage of AVI BioPharma (Nasdaq:AVII - News), raising its rating to Strong Speculative Buy and lowering its 12-month price target to $6.00. The 13-page report by Dutton senior analyst Stephen L. Handley is available at www.jmdutton.com, and at First Call, Bloomberg, Knobias, Zacks, Reuters, and other leading financial portals.


We continue to be impressed with the broad applicability and promise of AVI's differentiated technology in the treatment of many diseases. The stock has been quite volatile since we initiated research coverage last November, as investors have variously focused on the positive or negative implications of the news associated with one or more of AVI's products. For example, at one point there was a surge of investor interest in AVI and other companies developing products to combat avian flu, and later there was downward pressure on the stock because of a perceived setback in the development of a drug to treat hepatitis C. Indeed, it remains difficult to predict the near-term price movement for AVI as well as for most development stage healthcare companies. Nevertheless, we judge that the Company has many programs that, individually, could eventually generate significant earnings. So even though we have a near-term price target well above the current market price, we are in fact more confident about the likelihood that this stock will prove very rewarding to the long-term investor. We are raising our Speculative Buy rating to Strong Speculative Buy, while our price target, which had been raised during a period of strength in the stock reflecting our long-term optimism, is now back to our original $6.00 per share.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in the Dutton Associates one-year continuing research program is US $39,500 prepaid from the Company for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $33,000 from the Company for 4 Research Reports with coverage commencing on 11/16/2005. Dutton Associates does not accept payment of any of its fees in company stock. Its principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures, and analyst background at www.jmdutton.com before investing.



Contact:
Dutton Associates, LLC.
John M. Dutton, 916-941-8119

--------------------------------------------------------------------------------
Source: AVI BioPharma

[setravis]

Volume: 1,491,469
Avg Vol (3m): 787,263

Technicals
Percentage Gainer

Last Price Quote is:
22.30%above 13-day EMA
4.19%above 50-day EMA
RS Rating: 15 

Fundamentals
Key Data:
Market Cap (M): $174.67 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/10/2006
Last Analyst Rating: Mkt Outperform

[la-onda]

STRONG BUY REPORT:
http://www.jmdutton.com/research/avii/reports/avii_report_081806.pdf

[setravis]

  


AVI BIOPHARMA INC (NasdaqGM:AVII) Delayed quote data 

Last Trade: 4.40
Trade Time: 12:39PM ET
Change:  0.82 (22.91%)
Prev Close: 3.58
Open: 3.61
Bid: 4.40 x 1900
Ask: 4.42 x 2400
1y Target Est: 8.50

  Day's Range: 3.55 - 4.48
52wk Range: 2.05 - 9.20
Volume: 2,930,992
Avg Vol (3m): 754,394
Market Cap: 232.89M
P/E (ttm): N/A
EPS (ttm): -0.45
Div & Yield: N/A (N/A)

[la-onda]

AVI Shares Surge on Positive Outlook
Tuesday August 22, 3:46 pm ET
AVI Biopharma Shares Rise, Dutton Associates Analyst Points to Company's Promising Pipeline

NEW YORK (AP) -- Shares of biopharmaceutical company AVI Biopharma Inc. surged Tuesday, as investors agreed with a Dutton Associates report citing the company's strong pipeline of programs.

The stock gained 79 cents, or 22 percent, to reach $4.37 in afternoon trading on the Nasdaq as trading volume jumped to more than four times the average. Until recently, the stock had been on a several-month decline from its 52-week high of $9.20, reached in early February. A year ago, the stock traded at a low of $2.05.

On Friday, Dutton Associates analyst Stephen Handley upgraded AVI shares to "Strong Speculative Buy" from "Speculative Buy," citing the company's breadth of programs in development. He lowered his 12-month price target to $6 from $10, however, noting the stock's price volatility and difficulty in predicting near-term pricing.

"Indeed, it remains difficult to predict the near-term price movement for AVI as well as for most development-stage health care companies," he wrote in a note to investors. "Nevertheless, we judge that the company has many programs that, individually, could eventually generate significant earnings."

AVI develops treatments for life-threatening diseases based on antisense compounds called NeuGenes. The compounds are part of a movement in gene-targeted therapy, in which the drug will target only specific gene codes for a disease. By locking onto the target, the goal is to prevent the virus from replicating and taking on genetic material from its host to replicate itself.

"The reason there's no cure for viral infections is because they borrow host genetic material," said Michael Hubbard, director of investor relations at AVI. "That's why this shift is important, we feel it's where medicine is ultimately going to go."

The company's most advanced projects deal with cardiovascular drugs to prevent restinosis, which can occur after angioplasty and threatens to close the artery. The drug candidate, called Resten, is aimed at being delivered after a stent is inserted, through microparticles. It is currently in Phase II clinical trials.

AVI is also working with the Department of Defense to develop biodefense agents for anthrax, ebola and ricin. In addition, it is working with the DOD and the Centers for Disease Control to develop a treatment for dengue fever based on its technology. While the fever isn't a domestic threat, it does represent a concern to soldiers serving overseas in developing nations.

Other treatments in either preclinical or early-stage development include those focused on hepatitis C, West Nile Virus, SARS and influenza.

[Melf Elf]

Short- term Double Top at 4.48. 

[Melf Elf]

Short- term Double Top at 4.48. 

Double Top Target: 3.88 MADE.

Math:

Highs: 4.48
Low: 4.18

4.48 - 4.18 = 0.30 points....4.18 - 0.30 = Target 3.88